title: Value of MRI as a surrogate marker for PML in natalizumab long-term therapy.
authors.forename: I
authors.initials: I
authors.lastname: Ayzenberg
authors.forename: C
authors.initials: C
authors.lastname: Lukas
authors.forename: N
authors.initials: N
authors.lastname: Trampe
authors.forename: R
authors.initials: R
authors.lastname: Gold
authors.forename: K
authors.initials: K
authors.lastname: Hellwig
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects*; D015415:Biomarkers; D005260:Female; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000175:diagnosis* / Q000503:physiopathology; D008279:Magnetic Resonance Imaging; D000069442:Natalizumab; D013997:Time Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D000069442:Natalizumab